Medwave
-
This article is the third of a series of four editorials that report on Medwaves policies, including section policies, formal requisites according to article type, and guidelines for reviewers and authors, with special emphasis on publication and research ethics. The journal believes that it is important to publish its policies in the format of editorials in order to facilitate and ensure dissemination to our broader readership. This editorial describes the types of articles that the journal publishes, such as primary studies, review articles, case reports, letters, and commentaries, among others.
-
This article is the second of a series of four editorials that report on Medwaves policies, including section policies, formal requisites according to article type, and guidelines for reviewers and authors, with special emphasis on publication and research ethics. The journal believes that it is important to publish its policies in the format of editorials in order to facilitate and ensure dissemination to our broader readership. This editorial refers to the importance of using reporting guidelines, values and principles, peer review process, authorship issues and publication ethics.
-
In 2013, we wrote about the harm, waste and deception stemming from conducts adopted by the pharmaceutical industry, by concealing raw data and Clinical Study Reports (CSRs) from the regulators view when requesting the marketing patent. We described the case of Tamiflu (Roche), a drug that has been widely used in our population and profusely prescribed by physicians. Health authorities, entailing a great cost for the countries in the region, have also purchased it. In this editorial, we will show how the idea of using antivirals for prophylaxis and treatment of influenza took hold, starting from the first enthusiastic recommendations up to the systematic review published last month in the BMJ.